Benign neoplasm: Aortic body and other paraganglia

CD2_BENIGN_AORTICBODY_PARAGANGLIA

adenoma: The congenital absence of the thyroid gland.

Endpoint definition

↥

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — D35.6& Hospital discharge: ICD-9 — 2276 Cause of death: ICD-10 — D35.6& Cause of death: ICD-9 — 2276 2 out of 7 registries used, show all original rules.	28
4. Check minimum number of events None	28
5. Include endpoints None	28
6. Filter based on genotype QC (FinnGen only)	28

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy: 3
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: D35
Name in latin: Neoplasma benignum glomeris aortici

NAME	CD2_BENIGN_AORTICBODY_PARAGANGLIA
CONTROL_EXCLUDE
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	D356
HD_ICD_9	2276
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	D356
COD_ICD_9	2276
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Benign neoplasm: Aortic body and other paraganglia based on the number of shared cases.

Similar with more cases:

Similar with less cases:

Benign neoplasm: Aortic body and other paraganglia

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	176	106	67
Only index persons	151	96	55
Unadjusted period prevalence (%)
Whole population	0.00	0.00	0.00
Only index persons	0.00	0.00	0.00
Median age at first event (years)
Whole population	55.36	57.16	51.95
Only index persons	54.43	56.85	50.19

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	28	16	12
Unadjusted period prevalence (%)	0.01	0.01	0.01
Median age at first event (years)	48.78	46.13	52.31

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

No data available

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(4035726)

4.46

2.06

1.5

1.3

—

(3019225) pH of Specimen

3.52

1.68

1.8

3.0

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

2.62

1.43

3.3

2.5

—

(3021879) Hepatitis B virus core Ab [Presence] in Serum

2.90

1.39

1.7

1.3

—

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

0.00

1.26

0.0

2.7

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

2.46

1.20

1.4

1.7

—

(3044640) Blood type and Crossmatch panel - Blood

2.28

1.14

3.7

2.4

—

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

0.00

1.04

0.0

2.6

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

101

2.04

0.98

4.9

4.0

—

(40768804) Tissue Pathology biopsy report

1.99

0.90

1.5

2.0

—

(3003694) ABO and Rh group [Type] in Blood

2.02

0.87

1.3

1.5

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

2.04

0.84

1.7

1.5

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

0.00

0.84

0.0

2.8

—

(43054914) Glucose tolerance 2 hours panel - Serum or Plasma

0.00

0.83

0.0

1.9

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

1.85

0.82

1.7

2.0

—

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

2.03

0.72

2.2

1.5

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

1.88

0.67

2.8

1.6

—

(40758558) Short blood count panel - Blood

1.81

0.64

12.8

9.3

—

(3023368) Bacteria identified in Blood by Culture

1.73

0.63

7.8

4.2

—

(3022621) pH of Urine by Test strip

0.00

0.63

0.0

2.5

—

(40761536) Microorganisms panel - Urine sediment

0.00

0.63

0.0

3.5

—

(3018418) pH of Serum or Plasma

1.77

0.60

7.9

5.0

—

7.4

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

1.68

0.57

2.5

1.6

—

(3012544) pH of Venous blood

1.81

0.47

5.0

8.8

—

(3013512) EKG study

1.50

0.46

4.1

3.9

—

(3009445) Proteinase 3 Ab [Units/volume] in Serum

0.00

0.42

0.0

1.1

—

(42870588) Differential panel, method unspecified - Blood

1.56

0.42

6.5

8.3

—

(3013707) Erythrocyte sedimentation rate by Westergren method

166

1.45

0.37

3.6

4.4

11.5

11.2

mm/h

0.04

152

(3041096) Erythrocytes [Presence] in Urine by Automated

0.67

0.31

3.0

3.6

—

(3013650) Neutrophils [#/volume] in Blood by Automated count

137

1.39

0.28

16.0

11.6

4.9

4.2

e9/l

0.40

115

(1002224) Polysomnography panel

0.00

0.22

0.0

1.1

—

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

0.00

0.22

0.0

1.1

—

(3016251) Hemoglobin.gastrointestinal [Presence] in Stool

0.00

0.22

0.0

2.0

—

(21492888) Glucose tolerance 2 hours gestational panel - Serum or Plasma

0.00

0.22

0.0

1.4

—

(3029511) Human papilloma virus DNA [Presence] in Specimen by NAA with probe detection

0.00

0.22

0.0

1.5

—

(3049717) Cytology report of Urine Cyto stain

0.00

0.22

0.0

1.8

—

(3020321) Streptococcus agalactiae [Presence] in Vaginal fluid by Organism specific culture

0.00

0.22

0.0

1.5

—

(3044491) Cholesterol non HDL [Mass/volume] in Serum or Plasma

0.00

0.22

0.0

1.3

—

(3045414) Leukocytes [Presence] in Urine

0.00

0.21

0.0

1.4

—

(3011371) Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection

0.00

0.21

0.0

2.6

—

(3002109) Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma

0.00

0.20

0.0

1.7

—

(3052851) Hemolysis interference index of Serum or Plasma

0.00

0.20

0.0

2.7

—

(3026008) Bacteria identified in Urine by Culture

0.76

0.18

2.7

3.4

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

147

0.78

0.17

2.7

3.2

—

(3035350) Ketones [Presence] in Urine by Test strip

116

0.79

0.15

2.8

3.9

—

0.0

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

1.20

0.10

1.5

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

0.82

0.08

3.3

3.7

—

(3015736) pH of Urine

1.17

0.06

2.7

3.3

—

(3037467) Urinalysis macro (dipstick) panel - Urine

160

0.87

0.06

3.0

4.7

—

(3044889) 12 lead EKG panel

150

0.87

0.06

3.9

3.5

—

(3021601) Nitrite [Presence] in Urine by Test strip

113

0.96

0.00

4.2

5.2

—

0.0

—

(3009261) Glucose [Presence] in Urine by Test strip

115

0.93

0.00

2.6

3.9

—

0.0

—

(3028300) Cannabinoids [Presence] in Urine

0.00

0.0

1.4

—

(3027008) Opiates [Presence] in Urine

0.00

0.0

1.4

—

(4034850)

0.00

0.0

25.2

—

(3000764) Benzodiazepines [Presence] in Urine

0.00

0.0

1.4

—

(3035797) Protein.monoclonal band 2 [Mass/volume] in Serum or Plasma by Electrophoresis

0.00

0.0

1.3

—

0.0

—

(3016879) Cocaine [Presence] in Urine

0.00

0.0

1.4

—

(3017895) Helicobacter pylori Ab [Units/volume] in Serum

0.00

0.0

1.6

—

(3027944) Amphetamines [Presence] in Urine

0.00

0.0

1.4

—

(3003191) Choriogonadotropin (pregnancy test) [Presence] in Serum or Plasma

0.00

0.0

2.1

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

0.90

0.00

2.9

3.9

—

(40768793) Breast Pathology biopsy report

0.00

0.0

1.0

—

(1001926) Buprenorphine [Presence] in Urine by Screen method

0.00

0.0

1.1

—

(36305247) Microscopic observation [Identifier] in Isolate by Gram stain

0.00

0.0

1.2

—

(3012477) Bordetella pertussis DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.0

—

(3042631) Mycobacterium sp identified in Specimen

0.00

0.0

5.8

—

(3008909) Norovirus RNA [Presence] in Stool by NAA with probe detection

0.00

0.0

1.6

—

(3020565) Legionella pneumophila DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.0

—

(3029379) Protein.monoclonal band 4 [Mass/volume] in Serum or Plasma by Electrophoresis

0.00

0.0

1.1

—

0.0

—

(3051611) Lipemic interference index of Serum or Plasma

0.00

0.0

2.3

—

(3014051) Protein [Presence] in Urine by Test strip

0.00

0.0

1.7

—

(3031478) Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.0

—

(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay

0.00

0.0

1.3

—

(3017766) Complement C4 [Mass/volume] in Serum or Plasma

0.00

0.0

1.1

—

0.2

—

(3051651) Icteric interference index of Serum or Plasma

0.00

0.0

2.0

—

(3002482) Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.0

—

(3003327) Ova and parasites identified in Stool by Light microscopy

0.00

0.0

1.5

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

0.91

0.00

2.6

3.2

—

(3023150) Myeloperoxidase Ab [Units/volume] in Serum

0.00

0.0

1.3

—

(3002434) Lupus erythematosus deoxynucleoproteins IgG Ab [Units/volume] in Serum by Immunoassay

0.00

0.0

1.3

—

(3000620) Complement C3 [Mass/volume] in Serum or Plasma

0.00

0.0

1.1

—

1.1

—

(3049804) Myeloperoxidase IgG Ab [Units/volume] in Serum

0.00

0.0

1.0

—

(3027545) Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay

0.00

0.0

1.6

—

(3020460) C reactive protein [Mass/volume] in Serum or Plasma

219

1.02

0.00

26.6

14.3

14.7

19.9

mg/l

0.68

165

(3010726) Horse dander IgE Ab [Units/volume] in Serum

0.00

0.0

1.0

—

(3001019) Free T4 and TSH panel - Serum or Plasma

0.00

0.0

1.6

—

(1002102) Choriogonadotropin.intact+Beta subunit [Mass/volume] in Serum or Plasma

0.00

0.0

1.6

—

(3006588) Cancer Ag 15-3 [Units/volume] in Serum or Plasma

0.00

0.0

3.6

—

19.4

—

(3036086) Jo-1 extractable nuclear Ab [Units/volume] in Serum by Immunoassay

0.00

0.0

1.0

—

(3011288) Drugs identified in Urine by Screen method

0.00

0.0

1.8

—

(40762119) U1 small nuclear ribonucleoprotein 70kD Ab [Units/volume] in Serum

0.00

0.0

1.0

—

(3023511) Choriogonadotropin [Units/volume] in Urine

0.00

0.0

1.6

—

(3004383) Neutrophil cytoplasmic Ab.classic [Titer] in Serum by Immunofluorescence

0.00

0.0

1.2

—

(3029338) Protein.monoclonal band 3 [Mass/volume] in Serum or Plasma by Electrophoresis

0.00

0.0

1.1

—

0.0

—

Mortality – FinRegistry

↥

Association

Association between endpoint CD2_BENIGN_AORTICBODY_PARAGANGLIA and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have CD2_BENIGN_AORTICBODY_PARAGANGLIA.

N-year risk	Females	Males
1	No data	No data
5	No data	No data
10	No data	No data
15	No data	No data
20	No data	No data

Relationships between endpoints

↥

Index endpoint: CD2_BENIGN_AORTICBODY_PARAGANGLIA – Benign neoplasm: Aortic body and other paraganglia

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Benign neoplasm: Aortic body and other paraganglia

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints